{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T14:01:36Z","timestamp":1784988096395,"version":"3.55.0"},"reference-count":47,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Despite recent advances in the treatment of locally advanced non-small cell lung cancer (NSCLC), most patients relapse after definitive chemoradiotherapy followed by durvalumab consolidation. Due to limited evidence on post-relapse management, no standard treatment approach has been established for this patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The objective of this study was to evaluate real-world treatment strategies and clinical outcomes in patients with NSCLC who experienced disease recurrence after durvalumab consolidation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>This was a multicenter, retrospective cohort study conducted across 12 German lung cancer centers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A total of 145 patients with recurrent NSCLC following chemoradiotherapy and durvalumab consolidation were analyzed. Clinical, pathological, and treatment-related data were collected, including smoking status, histology, molecular testing, therapeutic sequences, and survival outcomes. Overall survival (OS) and progression-free survival (PFS) were estimated and compared across subgroups according to relapse characteristics and post-relapse treatment strategies. Multivariate analyses were performed to identify independent prognostic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The median OS from initial diagnosis was 27.1\u2009months (95% confidence interval (CI): 22.5\u201331.8). After relapse, median OS was 12.2\u2009months (95% CI: 9.9\u201314.4), and median PFS was 7.1\u2009months (95% CI: 5.7\u20138.4). Approximately 70% of patients received systemic therapy after relapse, including platinum-based chemotherapy (18.6%), single-agent chemotherapy (18.6%), immune checkpoint inhibitors with or without chemotherapy (28.3%), and targeted therapy (4.8%). Patients treated with immune checkpoint inhibitors or targeted therapies showed a numerical improvement in OS compared with chemotherapy alone, although this difference did not reach statistical significance. Multivariate analysis identified first-line post-relapse treatment, Eastern Cooperative Oncology Group performance status, and histologic subtype as independent prognostic factors for OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Patients with relapsed NSCLC after durvalumab consolidation have a poor prognosis and remain a therapeutically underserved population. Clinical outcomes appear to be influenced by performance status, histology, and the choice of post-relapse therapy. Prospective clinical trials are urgently needed to define optimal treatment strategies for these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359261453565","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:10:50Z","timestamp":1784826650000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical management and outcomes of relapsed NSCLC after chemoradiotherapy and durvalumab consolidation: real-world evidence from Germany"],"prefix":"10.1177","volume":"18","author":[{"given":"Georg","family":"Evers","sequence":"first","affiliation":[{"name":"Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital M\u00fcnster, M\u00fcnster, Nordrhein-Westfalen 48149, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Glanemann","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Hospital Essen Westdeutsches Tumorzentrum, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Webend\u00f6rfer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Hospital Essen Westdeutsches Tumorzentrum, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Wiesweg","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Hospital Essen Westdeutsches Tumorzentrum, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"G\u00f6rlich","sequence":"additional","affiliation":[{"name":"Institute of Biostatistics and Clinical Research, University of M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Christoph","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Evangelische Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Hoffknecht","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Franziskus-Hospital Harderberg\u2014Niels-Stensen-Kliniken GmbH, Georgsmarienh\u00fctte, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Pius-Hospital Oldenburg, University of Oldenburg, Oldenburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Acker","sequence":"additional","affiliation":[{"name":"Department of Medicine 2, Hematology and Oncology, University Hospital, Goethe University Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Sebastian","sequence":"additional","affiliation":[{"name":"Department of Medicine 2, Hematology and Oncology, University Hospital, Goethe University Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kerkhoff","sequence":"additional","affiliation":[{"name":"Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mohr","sequence":"additional","affiliation":[{"name":"Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[{"name":"Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Carina","family":"Hund","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Universit\u00e4tsmedizin G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias R.","family":"Overbeck","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Universit\u00e4tsmedizin G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7452-7129","authenticated-orcid":false,"given":"Nikolaj","family":"Frost","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Pneumology, Universit\u00e4tsklinik Charit\u00e9\u2014Campus Virchow Klinikum, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2439-7538","authenticated-orcid":false,"given":"Martin","family":"Faehling","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Angiology and Pneumology, Klinikum Esslingen, Esslingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7039-0791","authenticated-orcid":false,"given":"Wolfgang M.","family":"Br\u00fcckl","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Allergology and Sleep Medicine, General Hospital Nuremberg, Paracelsus Medical University, Nuremberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Kropf-Sanchen","sequence":"additional","affiliation":[{"name":"Pulmonology Department, University Hospital Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Sch\u00fctte","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Hospital Martha-Maria Halle-D\u00f6lau, Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Griesinger","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Pius-Hospital Oldenburg, University of Oldenburg, Oldenburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4651-0615","authenticated-orcid":false,"given":"Lea E.","family":"Reitnauer","sequence":"additional","affiliation":[{"name":"Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalen","family":"Bleckmann","sequence":"additional","affiliation":[{"name":"Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2020.03.40"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.3569"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.7840"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01308"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402614"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2354160"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rrac057"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107294"},{"key":"e_1_3_4_12_2","unstructured":"National Comprehensive Cancer Network\u00ae. Non small cell lung cancer (version 05.2024) [Internet]. NCCN https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1450 (accessed 13 August 2024)."},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-3101"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0099"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13241"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.03.017"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-674"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2013.827657"},{"issue":"1","key":"e_1_3_4_20_2","first-page":"36","article-title":"Targeted therapy for non-small cell lung cancer: current standards and the promise of the future","volume":"4","author":"Chan BA","year":"2015","unstructured":"Chan BA, Hughes BGM. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res 2015; 4(1): 36\u201354.","journal-title":"Transl Lung Cancer Res"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.09.028"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-05490-8"},{"issue":"2","key":"e_1_3_4_23_2","first-page":"215","article-title":"Primary and acquired resistance to immunotherapy with checkpoint inhibitors in NSCLC: from bedside to bench and back","volume":"39","author":"Mariniello A","year":"2025","unstructured":"Mariniello A, Borgeaud M, Weiner M, et al. Primary and acquired resistance to immunotherapy with checkpoint inhibitors in NSCLC: from bedside to bench and back. BioDrugs Clin Immunother Biopharm Gene Ther 2025; 39(2): 215\u2013235.","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.21037\/cco-25-3"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2017-0052"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0375"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102303"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2023.04.008"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108576"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00689-z"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.12.017"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-023-04547-2"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-015-0929-3"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.08.034"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.10.005"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.013"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30532-0"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00201"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3501"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8609"},{"key":"e_1_3_4_41_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.09.081","article-title":"LBA69 SKYSCRAPER-03: phase III, open-label, randomised study of atezolizumab (atezo)\u2009+\u2009tiragolumab (tira) vs durvalumab (durva) in locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) after platinum-based concurrent chemoradiation (cCRT)","volume":"36","author":"Dziadziuszko R","year":"2025","unstructured":"Dziadziuszko R, Ahn MJ, Bradley JD, et al. LBA69 SKYSCRAPER-03: phase III, open-label, randomised study of atezolizumab (atezo)\u2009+\u2009tiragolumab (tira) vs durvalumab (durva) in locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) after platinum-based concurrent chemoradiation (cCRT). Ann Oncol 2025; 36: S1610\u2013S1611.","journal-title":"Ann Oncol"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2022.04.003"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.01.1628"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.12.020"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.02.014"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.009"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.003"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.7293"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261453565","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359261453565","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261453565","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T13:16:27Z","timestamp":1784985387000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359261453565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":47,"alternative-id":["10.1177\/17588359261453565"],"URL":"https:\/\/doi.org\/10.1177\/17588359261453565","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"17588359261453565"}}